Disease relevance of Argun

• Alclofenac is a non-steroidal anti-inflammatory agent advocated for use in rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis [1].
• Forty-six patients with rheumatoid arthritis, 22 receiving D-penicillamine and 2j alclofenac, took part in a 6-month single-bind external observer trial to compare the efficacy and toxicity of these drugs in the treatment of severe rheumatoid arthritis [2].
• Clinical studies on alclofenac in the treatment of rheumatic diseases: a drug in question [3].
• The incidence of side-effects was slightly higher in the aspirin group but a high incidence of skin rash (30% approx.) was recorded with alclofenac tablets [4].
• The epoxide, but not alclofenac itself, showed mutagenic effects on strains of Salmonella typhimurium sensitive to alkylating agents, but had no effect on strains sensitive to intercalating agents [5].

High impact information on Argun

• Effect of food on kinetics of the nonsteroidal anti-inflammative, alclofenac [6].
• Alclofenac: a review of its pharmacological properties and therapeutic efficacy in rheumatoid arthritis and allied rheumatic disorders [1].
• The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite [7].
• No evidence was obtained for metabolism of alclofenac in control microsomes although in induced microsomes alclofenac was metabolised to both the dihydroxy (DHA) and phenolic (4-hydroxy-3-chlorophenyl acetic acid: HCPA) metabolites [7].
• Significant destruction of cytochrome P-450 was observed when alclofenac was incubated with microsomes from mice pretreated with PB but not from untreated or 3-MC-treated mice [7].

Biological context of Argun

• MFP and P-NaF showed greater bioavailability than Neosten and much higher Cmax that exceeded the toxic threshold of Fser (190 ng/ml) [8].
• Hydrolysis of urine with strong alkali resulted in the decomposition of alclofenac [9].
• The simultaneous pharmacokinetics of alclofenac in the plasma and synovial fluid of 10 patients with rheumatoid arthritis were studied after a single 1 g. oral dose [10].
• In human volunteers given alclofenac at therapeutic dose levels, no mutagenic activity was found in the urine and no significant increase in the incidence of structural chromosome aberrations was observed in peripheral blood lymphocytes [11].
• In vitro and in vivo effects of alclofenac on platelet aggregation: correlation with plasma levels in man [12].

Anatomical context of Argun

• A gas-liquid chromatographic method was used for assaying alclofenac in both plasma and synovial fluid [10].
• The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis [13].

Associations of Argun with other chemical compounds

• A biochemical comparison of alclofenac and D-penicillamine in rheumatoid arthritis [14].
• A double-blind cross-over study using a double placebo technique was employed to compare the effectiveness of daily alclofenac 3 g and phenylbutazone 300 mg in rheumatoid arthritis [15].
• The stable metabolites DHA and HCPA caused no loss of cytochrome P-450 whereas the reactive intermediate, alclofenac epoxide, was a potent inducer of destruction in the absence of NADPH [7].
• A comparison of fluoride bioavailability from a sustained-release NaF preparation (Neosten) and other fluoride preparations [8].
• Treatment of rheumatoid arthritis with tolmetin: a comparison with alclofenac [16].

Gene context of Argun

• C-reactive protein (CRP) levels were measured in 105 patients with rheumatoid arthritis (RA) during treatment with slow-acting anti-rheumatoid drugs D-penicillamine, alclofenac, hydroxychloroquine, gold, sulphasalazine and azathioprine [17].
• Double-blind comparison of alclofenac and aspirin in the treatment of rheumatoid arthritis. Part II: high dosage regime for assessment of analgesic and anti-inflammatory activity [4].
• The mean ESR fell markedly in patients on gold, but in those on alclofenac it showed no consistent change [18].

Analytical, diagnostic and therapeutic context of Argun

• Twenty-three patients completed the trial; eight patients were withdrawn while on alclofenac, six developing a rash and two having inadequate analgesia [15].
• An epoxide metabolite has been identified in the urine of normal volunteers and rheumatoid arthritis patients after the oral administration of alclofenac (1.5--4 g daily) [19].
• Determination of alclofenac in equine plasma and urine by high-performance liquid chromatography [9].
• The effect of 3 different oral NSAIDs, namely indomethacin, Alclofenac, and flufenamic acid, on menstrual blood loss (MBL) and pain among women fitted with copper IUDs was studied and compared with a placebo on a randomized single blind basis [20].
• Disposition of human drug preparations in the horse. III. Orally administered alclofenac [21].

References